The treatment of toxoplasmic uveitis.
D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001623:Betamethasone / Q000627:therapeutic use; D002415:Cats; D002833:Choroiditis / Q000188:drug therapy / Q000209:etiology; D003452:Cryosurgery; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use*; D011739:Pyrimethamine / Q000009:adverse effects / Q000627:therapeutic use*; D012173:Retinitis / Q000150:complications / Q000188:drug therapy; D014126:Toxoplasmosis, Ocular / Q000150:complications / Q000188:drug therapy*; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology; D015047:Zoonoses
D003907:Dexamethasone; D003520:Cyclophosphamide; D000324:Adrenocorticotropic Hormone; D001623:Betamethasone; D011239:Prednisolone; D011241:Prednisone; D008775:Methylprednisolone; D008727:Methotrexate; D011739:Pyrimethamine